Quantitative Structure–Activity Relationship and Molecular Docking Studies of Imidazolopyrimidine Amides as Potent Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Leila Emami, Razieh Sabet, Amirhossein Sakhteman & Mehdi Khoshnevis Zade · Journal of Pharmaceutical Research International · 2019
Type 2 diabetes (T2DM) is a metabolic disorder disease and DPP-4 inhibitors are a class of oral hypoglycemic that blocks the dipeptidyl peptidase-4 (DPP-4) enzyme. DPP-4 inhibitors reduce glucagon and blood glucose levels and don’t have side effects such as hypoglycemia or weigh...
Open access
Research Article
10.9734/jpri/2019/v27i630186